Background: Hematologic toxicity (HT) commonly occurs during chemoradiation therapy (CRT) for esophageal cancer. We sought to determine radiation doses that correlate with declines in blood counts due to vertebral body (VB) irradiation during CRT.
Introduction
Esophageal cancer is a leading cause of cancer morbidity and mortality, contributing to 442,000 new cases and 440,000 deaths globally in 2013 (1) . In the United States, although there were 17,000 reported new cases of esophageal cancer in 2016, the 5-year overall survival (OS) based on national data remains low at 18% (2) . Surgery has traditionally been the mainstay for localized esophageal cancer, but it alone results in high locoregional failure rates ranging from 30-60% (3) (4) (5) (6) .
The central role of radiotherapy in the management of esophageal cancer was established through several seminal trials studies which established trimodality treatment as the standard of care in locally advanced esophageal cancer (7) (8) (9) . These randomized data showed that neoadjuvant chemoradiation (CRT) doubles 3-year OS rates from 6-16% to 30%. Also pathologic complete responses (pCR) improve from 5-15% with neoadjuvant chemotherapy alone to 20-30% using neoadjuvant chemoradiation (7) (8) (9) . In 2008, Tepper et al. reported that trimodality therapy resulted in a 5-year survival rate of 40% compared to surgery alone (10) . Clinical toxicities of CRT include expected grade ≥3 esophagitis (42%); however, more than half of the patients experienced at least one occurrence of grade ≥3 hematologic toxicity (HT) (57%). HT can result in dose-reductions, interruptions in chemotherapy, or potentially unplanned radiation treatment breaks (11) .
While trials such as the CALGB 80803, PRODIGE5, and PROTECT-1402 employ multidrug regimens which may improve they efficacy of treatment, they often do so at the cost of increasing the rates of grade ≥3 HT (12) (13) (14) . Nevertheless, RT likely also contributes to HT when given in combination with chemotherapy.
We therefore hypothesized that radiation dose to the bone marrow was associated with development of HT in esophageal cancer patients who were treated with carboplatin-paclitaxel based CRT.
Methods

Patient population
After an institutional review board-approval, we retrospectively reviewed a total of 97 patients who were managed with curative intent therapy (definitive CRT or preoperative CRT followed by surgery) from 2005-2015. For purposes of homogeneity and data interpretation, we included only patients who received preoperative carboplatin-paclitaxel and radiation therapy (15, 16) . Of the 97 patients screened with available weekly complete blood counts (CBC) with differentials during CRT, those who received colony-stimulating factors, a chemotherapy regimen other than carboplatin-paclitaxel, or did not complete a full course of chemoradiation were excluded, leaving 53 patients for consideration.
Treatment planning and delivery
Computed tomography (CT) scan simulation was performed with the patient in supine position with arms up in a wingboard with body immobilization. Vertebral bodies (VB) were contoured from the C2 to L2 vertebra or the most inferior complete vertebra visualized on simulation scans. Each vertebral contour included the body, pedicles, transverse processes, laminae, and the spinous processes. The spinal canal was excluded. The ribs, scapulae, and clavicles were contoured separately. Weekly intravenous carboplatin (area under the curve =2) and paclitaxel (50 mg/m 2 ) was delivered during radiation therapy. Fortyfour patients (83%) were treated to a dose of 5,040 cGy with either IMRT or 3D conformal radiation therapy (3DCRT) radiation. Three patients (5.7%) were treated to doses between 4,140-5,040 cGy and 5 patients (9.4%) all of whom had upper esophageal cancer were treated to doses between 5,040-7,000 cGy.
Evaluation
White blood cell (WBC), hemoglobin (Hgb), and platelet (Plt) counts were collected weekly starting from the onset of neoadjuvant chemoradiation, through the duration of treatment, and before each scheduled post-treatment followup for 90-120 days after CRT. The Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) was used to evaluate the grade of HT. Dose volume histogram (DVH) data were collected in percentages of VB V 10 -V 60 (VBV), thoracic rib V 10 -V 60 (TRV), scapula V 10 -V 60 , and clavicle V 10 -V 60 in increments of 10. VBV 5 , TRV 5 , scapula V 5 , clavicle V 5 , mean vertebral dose (MVD), mean rib dose (MRD), mean scapula dose (MSD), and mean clavicle dose (MCD) were collected as well. A DVH parameter of Vx was defined as the percentage of organ receiving at least x Gy of radiation.
Shapiro-Wilks test was performed to assess for normality of hematologic cell values. Non-normally distributed values were log transformed. Univariate and multiple linear regressions were performed to identify associations between WBC, Hgb, and Plt nadirs and DVH parameters. Multiple linear regression models were controlled for body mass index (BMI) and age at diagnosis as previous studies established these factors to be associated with WBC count nadir (17, 18) . The regression coefficient (β) was estimated and represents the change in mean WBC count for every 1-unit increase in corresponding DVH parameter. Univariate logistic regression was used to assess the risk of grade ≥3 HT with increasing DVH parameters. Receiver operating characteristic (ROC) curves were calculated to determine the dose thresholds for avoiding grade ≥3 HT. These thresholds correspond to the point closest to the upper left portion of the graph, which represents the highest accuracy of predicting HT. Data analyses were performed on SAS v9.3 (SAS Institute, Cary, NC, USA). Statistically significant P values were accepted at a level below 0.05.
Results
Patient characteristics
Patient characteristics are shown in Table 1 . Of the 53 patients included with locally advanced esophageal carcinoma, 37.7% (n=20) had squamous cell carcinoma and 62.3% (n=33) had adenocarcinoma. Sixty-six percent (n=35) presented with gastroesophageal (GE) junction cancer, 22.6% (n=12) presented with thoracic esophageal cancer, and 11.3% (n=6) presented with cervical esophageal cancer. The average primary tumor size was 76.1 cc (range, 8.4-231.1 cc) and 67.9% (n=36) were node positive at diagnosis. Mean age at diagnosis was 67 years (range, 34-90 years). There was no statistically significant correlation of leukopenia on linear regression with BMI or logistic regression analysis with gender, location of tumor, and histology.
HT rates
Descriptive characteristics of HT during CRT are shown in Table 2 . Mean and median baseline blood count values were WBC of 7.1 and 6.8 k/μL (range, 4.5-12.8 k/μL), Hgb of 12.6 and 13 k/μL (range, 9.2-15.5 k/μL), and Plts of 250.7 and 242.0 k/μL (range, 149-2,358 k/μL). Of the 53 patients included in this study, 5.7% (n=3) did not develop Table 3) . No patients developed grade 4 anemia or thrombocytopenia. Patient ANC levels were not available weekly due to the CBC being done without a differential analysis and could not be calculated for 22 of the 53 patients. All patient nadirs occurred within the timeframe of the chemoradiation treatment rather than after completion of CRT.
Dosimetric parameters associated with HT
On univariate linear regression, VBV 30 (β=−0.004; P=0.017), VBV 20 (β=−0.005; P=0.006), VBV 10 (β=−0.006; P=0.002), VBV 5 (β=−0.006; P=0.002), and MVD (β<−0.001; P=0.018) were negatively linearly associated with mean log transformed WBC nadir by percentage. Plots of the WBC nadir with respect to VBV 10 are shown in Figure 1 .
When controlled for BMI and age at diagnosis, multiple linear regression analyses ( Table 4 ) revealed that VBV 30 (β=−0.004; P=0.012), VBV 20 (β=−0.005; P=0.006), VBV 10 (β=−0.006; P=0.002), VBV 5 (β=−0.006; P=0.002), and MVD (β=−0.0001; P=0.011) were negatively correlated with mean log transformed WBC nadir by percentage of volume.
Irradiation of the ribs, clavicle, and scapula was not significantly associated with leukopenia. Anemia and thrombocytopenia were not associated with increased bone marrow irradiation of any structure. Clinical parameters (BMI, gender, age at diagnosis) and tumor/treatment parameters (GTV volume in cc, total RT dose, and number of fractions) were not associated with WBC nadirs.
Determining thresholds to avoid HT
ROC analysis was performed to determine cutoffs to avoid grade ≥3 leukopenia. These DVH cutoffs were V 10 <49.1%, VBV 20 <45.6%, and MVD <17.2 Gy (Figure 2) .
Discussion
Our study demonstrates that increasing low dose and mean radiation dose to the VB is significantly associated with development of leukopenia in esophageal cancer patients (20) . In female anal cancer patients who are node negative and positive respectively, cutoffs of PBM V 15 <68% and V 15 <44% were shown to decrease the risk of grade ≥3 leukopenia. Each 1% increase of PBM V 15 correlated to a WBC nadir decrease of about 0.02 k/μL (17) .
The hematologic benefits of sparing vertebral bone marrow are likewise generalizable. Previously published Suggested dose for vertebral V 20 (56.0% vs. 44.3%) and MVD (23.9 vs. 18.8 Gy) in that cohort of patients to avoid grade ≥3 leukopenia was similar to values found in this study. In the NSCLC study, both a TVV 30 of 28% and an MVD of 13.5 Gy were cutoffs associated with a 20% chance of grade ≥3 leukopenia. Efforts to spare the bone marrow in an attempt to reduce rates of HT can have several implications including improving the tolerance of concurrent chemotherapy, lowering the risk of infections, hospitalizations, fatal complications, and potentially impact survival outcomes in esophageal patients undergoing CRT (21) (22) (23) (24) . Recent studies have shown that decreases in HT have been observed in esophageal cancer patients receiving proton therapy because of improvement in the distribution of radiation low dose bath (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) Gy) compared to IMRT, VMAT, or 3DCRT photon plans (25) . Similarly, dosimetric analysis shows that passive scatter proton therapy can decrease HT in stage III NSCLC lung cancer patients, which is statistically correlated with an improvement of TVV 10 by around 30% compared with 3DCRT and IMRT treatment (26, 27) . In turn, improvements in HT may improve adherence to the chemotherapy treatment schedule, which has been shown to significantly correlate with worse patient survival outcomes in NSCLC patients; median OS was 6 months for patients with missed chemotherapy administration compared with 24.3 months for those receiving all doses (P=0.004) (28) .
As newer studies seek to improve tumor response and survival by intensifying chemotherapy, establishing reliable bone marrow radiation constraints is necessary to reduce the substantial rates of HT observed ( Table 5) . A study by Conroy et al. of esophageal cancer patients comparing oxaliplatin, fluorouracil, and leucovorin (FOLFOX) with radiotherapy to the established 5-FU and cisplatin regimen showed that both arms had similar 3-year progression free survival (17-18%) and complete response (55-57%) (13) . However, grade ≥3 neutropenia was seen in nearly 30% of patients in both arms and more than 50% of patients experienced leukopenia, anemia, and thrombocytopenia. The phase II CALGB 80803 trial which utilized PETdirected pre-operative CRT initially randomized patients with resectable esophageal cancer either to an induction FOLFOX or carboplatin/paclitaxel arm. PET responders would continue the same chemotherapy concurrently with RT, but PET non-responders would receive concurrent RT with the other chemotherapy arm. Initial results showed a pCR rate 15.6% for those who were initially PET non-responders and 25.2% for PET responders (12) . HT rates were similar between patients randomized to either chemotherapy arm. Overall, patients experienced significant HT including 34% grade ≥3 lymphopenia, 13% grade ≥3 neutropenia, 7% grade ≥3 thrombocytopenia, and 6% grade ≥3 anemia.
Recent modeling studies in solid tumors such as gliomas and pancreas cancers have attributed this significant decrease in WBCs due to irradiation of the circulating blood lymphocytes. However, irradiation of peripheral lymphocyte alone most likely cannot solely contribute to the leukopenia see in esophageal cancer patients receiving chemoradiation. Radiation is known to cause predominantly induce interphase apoptotic death in lymphocytes with intact p53 pathways (29, 30) . At doses of 2 Gy, in vitro studies determined that the percent of lymphocytes undergoing apoptosis ranges from <10% to 20% (T4 and T8 cells) and around 35% (B cells) when corrected for cells undergoing spontaneous apoptosis without radiation (31, 32) . Also, while only 35% of the active bone marrow is found in the TV, the dose distribution of esophageal cancer patients treated with IMRT and 3DCRT often does not cover the entirety of T1-T12 vertebra, which suggests that only a small percent of the blood pool is being irradiated (33) . Potentially, the constant replenishing of the peripheral blood by active, non-irradiated bone marrow and the fact that lymphocytes only comprises 30% of the body's total WBC counts dispute the putative role of peripheral lymphocyte irradiation as the main contributor of leukopenia. More likely, a combination of bone marrow toxicity due to CRT and peripheral blood irradiation together contributes to the observed WBC nadirs.
Establishing and adopting bone marrow dose constraints is therefore a meaningful step to reduce HT and may allow for intensification of treatment combinations in esophageal cancer. Incorporation of bone marrow tolerances may lead to decreases in toxicity of therapy by reducing HT complications from patients undergoing chemoradiation and may allow for additional treatment intensification by incorporating additional systemic therapies (34) .
Conclusions
The volume of VB receiving low dose irradiation is more important of a predictive factor in limiting HT than the volume receiving high dose irradiation. Adaptation of VB dose constraints may decrease hematologic side effects and improve patient tolerance of therapy and resulting outcomes.
